Dental Growth Factor Extracts Panel Go-Ahead; Sankyo To Market GEM 21S
This article was originally published in The Gray Sheet
Executive Summary
BioMimetic Pharmaceuticals' GEM 21S synthetic bone-growth factor should be approved to treat osseous defects that result from periodontal disease, but not from other causes, FDA's Dental Products Panel recommended in Gaithersburg, Md. July 13
You may also be interested in...
BioMimetic Shifts Focus To Ortho Following Dental Combo Product Approval
BioMimetic Pharmaceuticals plans to initiate U.S. clinical studies for repairing bone fractures with device-biologic combination products in the first half of 2006
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.